Home›Trial›NCT05891171
🔬NCT05891171Phase 1ACTIVE NOT RECRUITING

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

Study Summary

The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.

Conditions
Advanced CancerAdvanced MalignanciesBladder CancerCervical CancerEsophageal CancerGastric CancerGastroesophageal-junction Cancer (GEJ)Head and Neck Squamous Cell Carcinoma (HNSCC)Non-Small Cell Lung Cancer (NSCLC)Ovarian CancerRenal Cell Carcinoma (RCC)Triple Negative Breast Cancer (TNBC)
Interventions / Drugs
AB598ZimberelimabFluorouracilLeucovorinOxaliplatin
View on ClinicalTrials.gov ↗
Sponsor
ARQT
Arcus Biosciences
Immuno-Oncology
F29/100
Study Details
Enrollment40 participants
Primary Completion—
Lead SponsorArcus Biosciences, Inc.
Data Retrieved2026-04-11 02:54:25.662810+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.